INTRODUCTION
Fibrosis, or excessive scar tissue formation, is a common pathologic pathway to organ failure. Likewise for tissues of the ocular surface, fibrosis is a serious and even sight-threatening concern. Conjunctival fibrosis is associated with chronic inflammatory conditions, such as in allergic eye disease; not necessarily in the mild or acute forms of seasonal or perennial allergic conjunctivitis, but rather in the more severe or chronic forms of vernal or atopic keratoconjunctivitis (AKC, VKC) [1] . Conjunctival fibrosis is also a concern in other chronic inflammatory diseases of the ocular surface, such as in mucous membrane pemphigoid [2] [3] [4] . In addition, although not reviewed here, corneal fibrosis is a clinically significant concern, and corneal involvement in allergic eye disease was recently described in mice [5 && ]. Here we review an emerging theme, which is the role of dendritic cells in the causation of scarring and tissue remodeling [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and relate this information to the pathobiology of conjunctival fibrosis in allergic eye disease. This topic is a fascinating one because dendritic cells, which are present in most if not all tissues, have a primary function in antigen presentation/stimulation of T lymphocytes. Thus, it has come as unexpected that dendritic cells can play a central role in fibroblast function/dysfunction. Indeed, as indirect players, dendritic cells have been
PATHOBIOLOGY OF CONJUNCTIVAL FIBROSIS
Excessive subepithelial accumulation of collagen and other extracellular matrix (ECM) proteins that occurs in conjunctival fibrosis can be particularly progressive. Although increased ECM production is indeed part of normal healing, the pathologic dysregulation of this process results in a state in which normal parenchyma is replaced with excessive and continual scarring that is permanent. In the conjunctiva, such responses cause forniceal shortening, and can progress to symblepharon and ankyloblepharon formation -in which excessive scar tissue has fused together the eyeball with the eyelids (Fig. 1) [21] .
Much of what is known about the underlying mechanisms in fibrosis is derived from studying how fibroblast activities differ in normal wound healing versus fibrosis settings. These cells are primarily responsible for homeostatic regulation of ECM. In a normal wound healing response, tissue resident fibroblasts migrate to the wound site, which is assisted through their expression of certain matrix metalloproteinases (MMP) [22] [23] [24] and cytoskeletal dynamics [22] . At the wound site, their contractile apparatus, collagen production, and tissue remodeling capacities are enhanced [25] [26] [27] [28] , which ultimately leads to wound closure and apoptosis of these migrated fibroblasts. In the case of fibrosis, in which scarring is excessive, fibroblasts, however, exhibit a pathologic phenotype that is maintained beyond the wound healing process. Fibroblasts explanted from fibrotic tissues, including the conjunctiva, produce abnormally heightened levels of collagen [4, [29] [30] [31] , have altered contractile abilities, and proliferative profiles [30, 32, 33] . This pathologic fibroblast is commonly known as the myofibroblast (Fig. 2) [34, 35] . These cells typically exhibit distinct a-smooth muscle actin stress filaments to increase contractility and strengthen ECM remodeling capacity ( Fig. 2 ), although their role remains unclear in conjunctival fibrosis.
Although the precise mechanisms underpinning the progression of normal to pathologic fibroblast responses have not been fully elucidated, chronic inflammation is very commonly associated with this process. There is a large literature involving the profibrotic role of macrophages, although recent studies suggest that certain macrophage populations can be reparative as well [19] . T lymphocytes are well documented as profibrotic through their production of certain cytokines, such as IL-13 [18, 19, 36] . These lymphocytes also act indirectly through activation and recruitment of neutrophils or eosinophils that express profibrotic cytokines, such as TNF-a, IL-1b or TGF-b. Last, an emerging theme in the literature is the role of dendritic cells in fibrosis [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , which we review in detail below.
KEY POINTS
Fibrosis is a common pathologic pathway to organ failure and is likewise a serious and sight threatening concern in allergic eye disease.
Whereas classical dendritic cells in mice include
CD11bþ and CD103þ subsets, which have functional equivalents in humans, it is the CD11bþ subset that plays the dominant role in allergic eye disease immunopathogenesis.
Recent work suggests that classical dendritic cells can play a central role in fibrosis pathobiology, which means that these cells may contribute to conjunctival fibrosis in allergic eye disease. Patients presenting with conjunctival fibrosis may begin to exhibit subepithelial fibrosis in which there is a sheet of scarring maintained underneath the epithelium. This can further develop into fornix shortening in which the area between the eyelid and globe becomes shallow because of building conjunctival scar tissue. Symblepharon formation then develops when bands of scar tissue begin to physically pull the eyelid toward the globe. Ankyloblepharon is end stage conjunctival fibrosis and this is where the globe and eyelid have fused together. Adapted from [21] .
DENDRITIC CELL BIOLOGY
There has been a recent explosion in our understanding of dendritic cells, namely in the development and function of classical dendritic cells (cDC), and it is important to appreciate this new information in order to accurately relate these cells potentially in fibrosis. cDCs are CD11cþ myeloidderived cells that exist constitutively in normal tissues. They are the foremost potent stimulators of T lymphocytes, and as such the main function of cDCs is antigen presentation. Antigen-laden dendritic cells undergo the process of maturation in order to stimulate T cells, which involves the increase in their cell surface expression of class II major histocompatibility complex (MHC II) and costimulatory molecules (CD80, CD86, CD40), which is modulated in part by thrombospondin-1 [37] . Maturation is accompanied by upregulation of the chemokine receptor CCR7, enabling dendritic cell migration into terminal lymphatics and ultimately to the T-cell-rich paracortical areas of the regional lymph node [38 && ]. Mature antigen-laden dendritic cells then come in contact with and stimulate cognate receptor bearing naïve or memory T cells, and assist in T helper ( H ) cell differentiation (i.e. T H 1, T H 2 and T H 17) [39 && ]. Their highly specialized function in T-cell stimulation means that it is of utmost importance to accurately identify cDCs. Features that do not distinguish cDCs per se are their morphology, that is, the appearance of long dendritic processes. This is because not only are the shapes of dendritic cells highly dynamic, other cells may have a dendritic appearance as well (e.g. epidermal gd T cells).
Expression of CD11c in itself is also not a distinguishable feature of dendritic cells, as macrophages express CD11c at significant levels (e.g. alveolar, splenic marginal zone, and thioglycolateinduced macrophages). In contrast, characteristics that positively distinguish cDCs are based on their unique developmental lineage ( Fig. 3 ). cDCs develop from precursor dendritic cells (predendritic cells), which arise from the common dendritic cell progenitor lineage (CDP) in definitive hematopoiesis ( Fig. 3 ). This distinguishes cDCs from another type known as plasmacytoid dendritic cells, which arise directly from CDPs as opposed to predendritic cells. This also distinguishes cDCs from so-called inflammatory/monocyte-derived dendritic cells, which do not originate from the CDP lineage ( 
Classical dendritic cells subsets and functions
It is now firmly established that cDCs comprise distinct and functionally specialized subsets [45] . Migratory (or nonlymphoid tissue) cDCs, that is, those that migrate from peripheral tissues to lymph nodes, exist in two main subsets. These can be differentially identified in part by their positive expression of integrin CD11b versus CD103 in nonlymphoid tissues throughout the body (Fig. 3) , with some exception in the intestinal tract [46] . Both populations are derived from the CDPs, although there is some debate as to whether monocytes may also give rise to CD11bþ cDCs to a small extent. Although the exact factors that govern . Our group has demonstrated the presence of bona-fide CD11bþ and CD103þ cDCs in the conjunctiva ( Fig. 4 ), through cell surface expression, transcription factor profiles and developmental lineage analyses [38 && ,49] . Similar studies have not been conducted in the cornea; however, we have identified the presence of corneal stromal dendritic cells that express the C-type lectin langerin and thus resemble CD103þ cDCs in the dermis [38 && ,50]. Also, the presence of CD11b expressing CD11cþ cells in the cornea is well documented, which may be akin to CD11bþ cDCs [51] .
Regarding the functional specialization of these subsets, our group has shown that conjunctival CD11bþ cDCs play the dominant role in the pathobiology of allergic eye disease, and blocking the chemokine receptor CCR7 expressed on these cells inhibits this process [38 && ,52,53,54 && ] ( Fig. 5 ). Dry eye disease shows a similar level of improvement to therapeutic CCR7 blockade ( Fig. 5) [54 && ]. The reasons why CD103þ cDCs are not involved in this setting are not fully understood, although reports have converged that such cDCs are instead crucial in triggering immune responses against certain viruses [55] . Likewise, it is not fully understood why CD11bþ cDCs are dominant in allergic eye disease, although a common theme for such cDCs has emerged in other allergy models as well, such as in asthma [56, 57] .
Langerhans cells
Langerhans cells are not cDCs. In fact, there is debate as to whether these cells should instead be classified as macrophages, because like most tissue resident macrophages (i.e. microglia, alveolar macrophages, Kupffer cells, etc.) they are derived from primitive (prenatal) not definitive (postnatal) hematopoiesis [42, 46] . Langerhans cells are relatively unique to the epidermis, in which they were originally identified and are found in very large numbers. These cells possess Birbeck granules/ organelles and express the C-type lectin langerin. It is inaccurate to assume that Langerhans cells exist universally in all other barrier tissues, or that all intraepithelial immune cells with a dendritic morphology are Langerhans cells. We have shown using (BAC transduced) human langerin mice [58, 59] that although Langerhans cells exist in the mouse cornea epithelium [50] , these cells only make up a very small fraction of CD11cþ cells in the corneal epithelium [11] . Regarding their function, whereas epidermal Langerhans cells in skin immune responses have been well characterized [58, 59] , their isolated role in the cornea is largely unknown.
CLASSICAL DENDRITIC CELLS IN FIBROSIS PATHOBIOLOGY
As previously mentioned, dendritic cell biology is an emerging theme in the fibrosis literature. For example, studies have incorporated in-vitro systems to help understand how mucosal and dermal fibroblasts influence dendritic cell function. Mouse models have also been incorporated, such as IL-1b induced airway remodeling or common bile duct ligation in liver, which have implicated dendritic cells in fibrosis pathobiology. Thus, whereas it has been recognized that cDCs contribute to fibrosis indirectly via activation of profibrotic T H cells, recent findings also point to the potential for a more direct means of triggering a profibrotic state. Though much of the work on this topic is focused on the inflammatory/monocyte-derived dendritic cells, these early studies may provide the conceptual framework by which future investigations can now probe how cDCs may directly effect fibroblast function/dysfunction.
Classical dendritic cells in T helper cellmediated fibrosis
T H 2 cells are the primary pathogenic subset in allergic diseases, although T H 1 and T H 17 can also play appreciable roles in certain settings [39 && ]. Interestingly, the T H 2 subset has emerged as a chief player in inducing and potentiating profibrotic activity [18, 19, 36, 60 && ], which explains the very high prevalence of fibrosis and tissue remodeling in chronic allergy. This proficiency of T H 2 is thought to be because of their expression of the highly profibrotic cytokine, IL-13 [18,19,36,60 && ]. Fibroblasts not only are activated by direct ligation of this cytokine, but also lead to augmented production of profibrotic TGF-b [19] . In comparison, T H 17 cells, which produce IL-17, are recognized in fibrosis, albeit this is mostly as a secondary consequence of inflammatory tissue damage [18, 19, 36, 60 && ]. Last, and in striking contrast, T H 1 responses are thought to be antifibrotic through IFN-g production [18, 19, 36, 60 && ,61], for reasons not fully understood.
In conjunctival fibrosis, IL-13 has also received considerable attention as a profibrotic factor. Leonardi et al. [61] showed that IL-13 (or IL-4) treated conjunctival fibroblasts had increased production of collagen and modified the equilibrium between MMP-1 and its inhibitor, TIMP-1. In a follow-up study, Leonardi et al. [62] reported that IL-13 was highly expressed in tears of patients with seasonal allergic conjunctivitis, AKC and VKC, thus linking the role of IL-13 and aberrant functionality of conjunctival fibroblast in allergic eye disease. This concept has been further supported in studies from mucous membrane pemphigoid patients by ex-vivo characterization of their primary conjunctival fibroblasts. These cells are functionally and morphologically abnormal [63] , and characterized by a profibrotic phenotype, for example, increased collagen production [2] [3] [4] . Furthermore, these patients have increased ocular surface levels of IL-13 [3] , and primary conjunctival fibroblasts exposed ex vivo with IL-13 display a profibrotic profile [3] . It should be noted that other factors relevant in allergic ocular inflammation have been associated with fibrosis, including histamine and nerve growth factor [64, 65] .
Classical dendritic cell-fibroblast crosstalk in coculture systems
As cDCs are positioned in close proximity to fibroblasts in the parenchyma, it is entirely conceivable that cross-regulation may occur between these two cell types and evidence exists to support this concept. Studies have revealed that fibroblasts have the potential to induce a diverse set of effects on cDCs, although it should be noted that much of this work is based on in-vitro studies using fibroblastconditioned media or cocultures with inflammatory/monocyte-derived dendritic cells. The latter are used, instead of cDCs, because of the feasibility for obtaining large numbers of cells through differentiation of peripheral blood monocytes. Using this system, several studies have reported an immunostimulatory role for fibroblasts. For example, Schirmer et al. [66] showed that IL-1b/ TNF-a stimulated human dermal fibroblasts produce prostaglandin E 2 , which in turn promotes proinflammatory cytokine IL-23 production by inflammatory/monocyte-derived dendritic cells and consequent T H 17 expansion in secondary cultures. Previous in-vitro studies have demonstrated that ICAM-1 and Thy-1 on dermal fibroblasts interact with b2 integrins on inflammatory/monocytederived dendritic cells [16] . This particular interaction not only promotes MMP-9 expression by inflammatory/monocyte-derived dendritic cells to assist in their migration in matrigel assays, but also leads to maturation of these dendritic cells [15] . Similar studies have not been conducted with conjunctival fibroblasts. TNF-a is, however, increased in the conjunctivae of patients with allergy and mucous membrane pemphigoid, and exposure of primary fibroblasts to TNF-a results in a profibrotic profile [2] .
In contrast, a report by Seguier et al. [17] demonstrates that fibroblasts can be immunosuppressive. Specifically, they showed that gingival fibroblasts inhibited differentiation of inflammatory/monocyte-derived dendritic cells and thereby reduced their consequent capacity to stimulate T-cell proliferation in subsequent mixed lymphocyte reactions. Consistently with this finding, Berthier et al. [9] demonstrated that murine fibroblasts inhibited IL-12 production from, and maturation of, splenic cDCs. Thus, whether inhibitory or stimulatory, fibroblasts may therefore have the potential to impact cDC function. Whether the reverse also occurs, however, that is, cDCs directly affecting fibroblast function, and if this type of regulation is relevant in conjunctival fibrosis are unknown.
Classical dendritic cell contribution in-vivo fibrosis models
In-vivo work to suggest crosstalk between cDCs and fibroblasts is not extensive, but there are some elegant studies that support this concept. For example, Kitamura et al. [20] showed in (allergen or IL-b induced) airway remodeling that cDC and inflammatory/monocyte-derived dendritic cell recruitment to the lung is dependent on fibroblast avb8--mediated activation of TGF-b. Whether, through this mechanism, fibroblasts directly recruit these cells or if recruitment is an ancillary effect of inflammation requires further investigation. Nonetheless, this process may be relevant in conjunctival fibrosis, as a role for TGF-b has been well documented. In another report, Connolly et al. [10] showed in a mouse model of liver fibrosis that CD11cþ expressing cells, via TNF-a, govern hepatic inflammation. Interestingly, increased levels and contribution of TNF-a have also been shown in conjunctival fibrosis [2] . It should be noted that CD11cþ cells shown by Connelly et al. likely represent the inflammatory/monocyte-derived type rather than bona-fide cDCs. Furthermore, whether cDCs directly contribute to fibrosis, rather than indirectly through tissue inflammation, remains to be determined.
Other studies point away from cDCs in the causation of fibrosis, and even go as far as to implicate a reparative function. A recent study by Pradere et al. [13] using a model of common bile duct ligation showed that hepatic macrophages contribute to liver fibrosis, as opposed to cDCs. The authors demonstrated that hepatic macrophages achieve this result in an IL-1 and TNF-mediated manner. In another study by Jiao et al. [11] cDCs were elegantly shown to actually promote the regression of liver fibrosis in mice. The authors demonstrated that resolution was partially dependent on dendritic cell expression of matrix metalloproteinase (MMP)-9.
CONCLUSION AND FUTURE DIRECTIONS
The following unifying hypothesis is based on the available literature and can be proposed for how cDCs may cause conjunctival fibrosis in allergic eye disease. This result may occur in multiple ways that are not mutually exclusive. One manner might be through CD11bþ cDC expression of proinflammatory TNF-a ( Fig. 6a) , which contributes to inflammation ( Fig. 6b ) and fibroblast activation (Fig. 6c ) [10] . Separately, CD11bþ cDCs may activate fibroblasts indirectly through stimulation of T H 2 [38 && ,49,52,53] , which produce IL-13 and TGF-b. This also leads to recruitment of eosinophils and consequent inflammation (Fig. 6a ) that furthers tissue damage [19, 36] . Activated fibroblasts, in turn, trigger or contribute to a positive feedback loop by contributing to inflammation (Fig. 6c) [20] , which leads to recruitment of inflammatory/monocyte-derived dendritic cells (Fig. 6d) [10, 20] , or additional CD11bþ cDCs [10, 20] to the allergic conjunctiva ( Fig. 6d ).
Perpetuation of this positive feedback in chronic forms of ocular surface inflammation, such as in VKC and AKC, may ultimately lead to fibrosis.
The question for future studies is whether cDCs can directly activate fibroblasts in the conjunctiva or elsewhere in a manner that ultimately leads to fibrosis. Indeed, cDCs can contribute to inflammation, which may lead to fibrosis secondarily. Also, cDCs can produce profibrotic factors, such as TGF-b; however, a wide array of cells make this cytokine and so the precise role of cDC-derived TGF-B is unclear. Thus, the question of whether cDCs directly cause fibrosis and whether this is relevant in allergic eye disease remains unresolved. The importance of addressing this question is not solely of academic merit, but may also be very useful in developing novel therapeutic strategies in the prevention or treatment of conjunctival fibrosis. 
